Cryoport Q4 FY2025 slides: CGT revenue surges 29% as margins expand

Cryoport reported Q4 revenue of $45.45M (+10% YoY) and full-year revenue of $176.2M (+12% organic), beating revenue consensus by ~$5M (3%) but missing EPS at -$0.27 vs -$0.21. Gross margin improved 271 bps to 47% and adjusted EBITDA improved by $12M to a -$5.8M FY loss (Q4 adj. EBITDA -$1.4M); the company holds $411M in cash and short-term investments vs $185M of senior convertible debt due Dec 2026. Management guided fiscal 2026 revenue of $190M–$194M (+8–10% organic); shares rose ~6.46% after-hours, indicating investor focus on revenue/margin momentum and a clear path toward profitability despite ongoing negative earnings.

Analysis

Cryoport’s setup looks like a classic scale-vs-execution story: entrenched platform advantages give real pricing and retention optionality as more therapies commercialize, but the near-term path trades on capital allocation and execution of capacity rollouts. The firm’s liquidity gives breathing room, yet the looming financing event is a binary: repayment/conversion decisions will be the clearest catalyst for either de-risking or material dilution within a 9–15 month window. Operationally, the highest-leverage variable is utilization of new facilities — a delayed approval cadence or slower ramp would compress margin expansion expectations disproportionately because fixed costs are being front-loaded. Finally, second-order supply-chain fragilities (cryogenic carrier availability, LN2 logistics, regulated cross-border transfers) create episodic spot-price power for providers that could both boost near-term realized pricing and invite rivals or internalized logistics programs from large sponsors over a multi-year horizon.

Key Decisions for Investors

• Long CYRX (constructive, tactical): Initiate a size-limited core position (3–5% portfolio) on any pullback within the next 3 months; horizon 9–18 months. Rationale: running-rate revenue durability + platform stickiness likely to drive multiple expansion as adjusted EBITDA inflects. Risk management: hedge with bought 12-month puts equal to 25% notional (cost≈1–2% portfolio) or set a 30% hard stop; targeted return 50–100% if operational acceleration continues.
• Options income entry (lower-cost long bias): Sell a 6–9 month put spread on CYRX, short a put ~20–30% OTM and buy a further OTM put for protection (net credit). This expresses a mildly bullish view while capping downside and collecting premium; assignment risk provides a lower effective basis if you want to accumulate stock. Use size where max loss ≤ 3% portfolio.
• Pair trade to isolate execution risk: Long CYRX / Short TMO (Thermo Fisher) sized 1:1 dollar exposure, duration 6–12 months. This isolates upside from CGT logistics share gains versus general lab-supply/large-cap logistics cyclicality; reduces macro-biotech beta and focuses P&L on Cryoport-specific operational execution. Trim if sector-wide funding conditions deteriorate.
• Event-driven short (speculative): If management elects to refinance the near-term convertible via a dilutive equity issuance rather than debt repayment, consider a small short position ahead of the announcement (size ≤1–2% portfolio) with tight stops. Catalysts: dilution would likely compress equity multiple quickly; target asymmetric payoff capturing >30% downside vs limited time exposure.